Last updated on August 2019

An Investigational Immuno-therapy Trial of Nivolumab or Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum-doublet Chemotherapy Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)


Brief description of study

The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.

Clinical Study Identifier: NCT02477826

Find a site near you

Start Over

Local Institution

Bunkyo-ku, Japan
3.3miles
  Connect »

Local Institution

Shinjuku-ku, Japan
4.22miles
  Connect »

Local Institution

Chuo-ku, Japan
6.96miles
  Connect »

Local Institution

Koto-ku, Japan
9.4miles
  Connect »